Cite
MLA Citation
Ofri Mosenzon et al.. “Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.” Lancet, vol. 7, no. 7, 2019, pp. 515–527. http://access.bl.uk/ark:/81055/vdc_100101398197.0x000004